Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Investing Activities (2021 - 2024)

Verrica Pharmaceuticals (VRCA) has 4 years of Cash from Investing Activities data on record, last reported at $8000.0 in Q4 2024.

  • For Q4 2024, Cash from Investing Activities rose 103.52% year-over-year to $8000.0; the TTM value through Dec 2025 reached -$8000.0, up 57.89%, while the annual FY2024 figure was -$19000.0, 94.75% up from the prior year.
  • Cash from Investing Activities reached $8000.0 in Q4 2024 per VRCA's latest filing, up from -$16000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $43.0 million in Q1 2022 and bottomed at -$22.1 million in Q2 2021.
  • Average Cash from Investing Activities over 4 years is $3.5 million, with a median of $8000.0 recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 296.98% in 2022, then plummeted 103.36% in 2023.
  • A 4-year view of Cash from Investing Activities shows it stood at $4.0 million in 2021, then soared by 68.39% to $6.8 million in 2022, then tumbled by 103.36% to -$227000.0 in 2023, then skyrocketed by 103.52% to $8000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $8000.0 in Q4 2024, -$16000.0 in Q3 2024, and -$11000.0 in Q2 2024.